

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2011 Army									DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev							
COST (\$ in Millions)	FY 2009 Actual	FY 2010 Estimate	FY 2011 Base Estimate	FY 2011 OCO Estimate	FY 2011 Total Estimate	FY 2012 Estimate	FY 2013 Estimate	FY 2014 Estimate	FY 2015 Estimate	Cost To Complete	Total Cost
Total Program Element	29.572	35.886	28.132	0.000	28.132	37.128	22.643	17.388	17.620	Continuing	Continuing
808: DOD DRUG & VACC AD	5.535	6.829	7.225	0.000	7.225	12.332	9.361	8.931	9.014	Continuing	Continuing
811: MIL HIV VAC&DRUG DEV	0.145	1.460	2.923	0.000	2.923	2.908	1.449	0.965	0.961	Continuing	Continuing
836: Field Medical Systems Advanced Development	13.343	22.822	17.984	0.000	17.984	21.888	11.833	7.492	7.645	Continuing	Continuing
837: SOLDIER SYS PROT-AD	6.561	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing
CS4: MEDICAL SYSTEMS ADV DEV INITIATIVES (CA)	3.988	4.775	0.000	0.000	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing
A. Mission Description and Budget Item Justification											
<p>This program element (PE) funds development of medical materiel at the start of an official program of record, within the early system integration portion of the System Development and Demonstration phase of the acquisition life cycle using 6.4 funding. Program efforts support transition of promising Science and Technology candidate medical technologies (drugs, vaccines, medical devices, diagnostics, and mechanisms for detection and control of disease carrying insects) to larger scale testing in humans for safety and effectiveness. Programs are aligned to meet Future Force (F2) requirements stressed within concept documents and organizational structures. The PE provides funding for Food and Drug Administration (FDA) regulated human clinical trials to gain additional information about safety and effectiveness on the path to licensure for use in humans. The major enablers supported by this PE are: Combat Casualty Care devices and biologics (products derived from living organisms), with two major focuses: 1) enhance forward care at the first responder level while reducing the footprint of medical organizations for greater mobility and easier sustainment, and 2) provide enhanced post-evacuation care and rehabilitation. The F2 concept places Soldiers into a more austere environment with lengthened evacuation times (both arrival and transit). Supporting medics and first responders require greater lifesaving and extended stabilization capability to save lives. Soldier Performance Enhancers in the form of drugs and diagnostics will allow commanders to manage a Soldier's mental and physical performance. Performance enhancers will increase Soldier capabilities and reduce casualties resulting from high operational tempo, extreme environmental exposure, and loss of cognitive ability. Infectious disease efforts include testing candidate vaccines and preventive and therapeutic drugs to reduce the risk of service members contracting debilitating or fatal diseases, and/or to shorten recovery time. Technologies for identifying disease threats and mechanisms for controlling disease-carrying insects will reduce risk of exposure. Disease and non-battle injuries (DNBI) are the largest contributors to the combat support hospital footprint, and significant reductions of the medical footprint in theater can be achieved by reducing the number of DNBI affected Soldiers. Military Human Immunodeficiency Virus (HIV) Vaccine and Drug Development funds militarily relevant HIV medical countermeasures. These include component development of candidate vaccines for large-scale field testing. This program is managed by U.S. Army Medical Materiel Development Activity (USAMMDA) and U.S. Army Medical Materiel Agency (USAMMA) of the US Army Medical Research and Materiel Command.</p>											

UNCLASSIFIED

R-1 Line Item #69

Page 1 of 41

369 of 1922

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2011 Army				DATE: February 2010	
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)		R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev			
B. Program Change Summary (\$ in Millions)					
	FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
Previous President's Budget	30.207	31.275	31.721	0.000	31.721
Current President's Budget	29.572	35.886	28.132	0.000	28.132
Total Adjustments	-0.635	4.611	-3.589	0.000	-3.589
• Congressional General Reductions		-0.164			
• Congressional Directed Reductions		0.000			
• Congressional Rescissions	0.000	0.000			
• Congressional Adds		4.775			
• Congressional Directed Transfers		0.000			
• Reprogrammings	0.000	0.000			
• SBIR/STTR Transfer	-0.635	0.000			
• Adjustments to Budget Years	0.000	0.000	-3.589	0.000	-3.589
Change Summary Explanation					
In FY 10, Funds increased (\$4611) due to Congressional directed research efforts.In FY 11, Funds realigned (\$3589) to higher priority requirements.					

UNCLASSIFIED

R-1 Line Item #69

Page 2 of 41

370 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army								DATE: February 2010			
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 808: <i>DOD DRUG & VACC AD</i>			
COST (\$ in Millions)	FY 2009 Actual	FY 2010 Estimate	FY 2011 Base Estimate	FY 2011 OCO Estimate	FY 2011 Total Estimate	FY 2012 Estimate	FY 2013 Estimate	FY 2014 Estimate	FY 2015 Estimate	Cost To Complete	Total Cost
808: <i>DOD DRUG & VACC AD</i>	5.535	6.829	7.225	0.000	7.225	12.332	9.361	8.931	9.014	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification <p>This project funds development of candidate medical countermeasures for infectious diseases of military relevance. These efforts are in: vaccines, drugs, diagnostic kits/devices, and insect control measures. These funds support human clinical efficacy (capacity to produce a desired size of an effect under ideal or optimal conditions) trials of the drug/vaccine in larger groups that are designed to assess how well the drug/vaccine works, and to continue safety assessments in a larger group of volunteers. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of medical diagnostic kits and devices. This work, which is performed in military laboratories or civilian pharmaceutical firms, is directed toward the prevention of disease, early diagnosis, and speeding recovery once diagnosed. All clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations, a mandatory obligation for all military products placed into the hands of medical providers or service members. Product development priorities are determined based upon four major factors: (1) the extent and threat of the disease within the Combatant Commands theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development and production).</p>											
B. Accomplishments/Planned Program (\$ in Millions)											
						FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total	
Program #1						5.535	0.000	0.000	0.000	0.000	
In FY 09, reviews evaluations, and human clinical trials of malarial/anti-malarial vaccines, drugs, diagnostics, insect repellents, and grouped infectious disease (Dengue [a severe debilitating disease caused by a virus and transmitted by a mosquito] and Leishmania [a skin-based disease caused by a parasite and transmitted by sand flies]) vaccines and drugs. For Tafenoquine, developed/validated new laboratory assay to determine levels of antibodies from malaria infection using blood samples from a mefloquine (current FDA-approved malaria drug) challenge clinical study (supported by project 849) and evaluated potential sites for future human safety/efficacy trial, and conducted a Critical Design Review (CDR). The Artesunate drug transitioned from project 810 and a Critical Design Review (CDR) was conducted. The Dengue Tetravalent Vaccine (DTV) vaccine continued FDA required vaccine potency and stability testing of the product and all other DTV activities are transitioned to project											

UNCLASSIFIED

R-1 Line Item #69

Page 3 of 41

371 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army				DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)		R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev		PROJECT 808: DOD DRUG & VACC AD		
B. Accomplishments/Planned Program (\$ in Millions)						
		FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
849. The Topical Antileishmanial Cream opened a human treatment protocol in the U.S., the industry partner continued stability testing and produced new clinical drug lots, and project 849 supports the overseas human trials activities of this topical cream. The Leishmania Skin Test (LST), will complete follow-up and performe data analysis for the expanded human safety/dose ranging/sensitization trial in the U.S. and conducted a Critical Design Review (CDR). The Pentostam drug transitioned to project 849. FY 2009 Accomplishments: FY 2009 FY 2010 Plans: FY 2010 FY 2011 Base Plans: FY 2011 Base FY 2011 OCO Plans: FY 2011 OCO						
Program #2 In FY10, for Tafenoquine, down-select to best site for human safety/efficacy trial and continue laboratory assay development/validation to understand the human body's immune responses when infected with malaria parasites and as tool for determining future clinical trial enrollment size, and transition the entire Tafenoquine program to project 849. Monitor progress of a new military topical insect repellent candidate in project 810 to determine its suitability for entry into advanced development. For the Infectious Disease Diagnostic (multiple candidates), conduct market research of selected developmental and commercial diagnostic platforms for select infectious diseases of military interest to determine suitability for entry into advanced development. The DTV vaccine continues FDA required vaccine potency and stability testing and all other DTV activities are transitioned to project 849. For the Topical Antileishmanial Cream, continue a human treatment protocol in the U.S., the partner		0.000	6.687	0.000	0.000	0.000

UNCLASSIFIED

R-1 Line Item #69

Page 4 of 41

372 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army			DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)	R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev	PROJECT 808: DOD DRUG & VACC AD			
B. Accomplishments/Planned Program (\$ in Millions)					
	FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
will continue stability testing and produce new clinical drug lots, and project 849 supports the overseas human clinical trials activities of this topical cream. For LST, complete the final report for the expanded human safety dose ranging sensitization trial in the U.S., and conduct pre-trial activities for a large scale (>200 subjects) human safety/efficacy trial in a Leishmania endemic region. FY 2009 Accomplishments: FY 2009 FY 2010 Plans: FY 2010 FY 2011 Base Plans: FY 2011 Base FY 2011 OCO Plans: FY 2011 OCO					
Program #3 In FY11, will prepare to accept transition of a new military topical insect repellent from project 810 at Milestone B into Engineering & Manufacturing Development phase. Will transition new malaria vaccine candidate from project 810 into Engineering & Manufacturing Development phase. For the Infectious Disease Diagnostic (multiple candidates), will prepare to accept transition of project into the Engineering & Manufacturing Development phase of advanced development. The DTV vaccine will continue FDA required vaccine potency and stability testing and all other DTV activities are transitioned to project 849. For Topical Antileishmanial Cream, will continue a human treatment protocol in the US, the industry partner will continue stability testing of the drug product, and project 849 supports the overseas human trials activities of the topical cream.	0.000	0.000	7.225	0.000	7.225

UNCLASSIFIED

R-1 Line Item #69

Page 5 of 41

373 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army			DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)	R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev	PROJECT 808: DOD DRUG & VACC AD			
B. Accomplishments/Planned Program (\$ in Millions)					
	FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
FY 2009 Accomplishments: FY 2009					
FY 2010 Plans: FY 2010					
FY 2011 Base Plans: FY 2011 Base					
FY 2011 OCO Plans: FY 2011 OCO					
Program #4 Small Business Innovative Research/Small Business Technology Transfer Programs.	0.000	0.142	0.000	0.000	0.000
FY 2009 Accomplishments: FY 2009					
FY 2010 Plans: FY 2010					
FY 2011 Base Plans: FY 2011 Base					
FY 2011 OCO Plans: FY 2011 OCO					
Accomplishments/Planned Programs Subtotals	5.535	6.829	7.225	0.000	7.225

UNCLASSIFIED

R-1 Line Item #69

Page 6 of 41

374 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army		DATE: February 2010
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 808: <i>DOD DRUG & VACC AD</i>
<u>C. Other Program Funding Summary (\$ in Millions)</u> N/A		
<u>D. Acquisition Strategy</u> Test and evaluate in-house and commercially developed products in extensive government-managed clinical trials to gather data required for FDA licensure and Environmental Protection Agency registration.		
<u>E. Performance Metrics</u> Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.		

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army											DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 808: <i>DOD DRUG & VACC AD</i>					
 Product Development (\$ in Millions)													
				FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	C	Nothing entered for Activity and Location. Location could not be determined.	5.952	1.750		1.869		0.000		1.869	Continuing	Continuing	0
Subtotal			5.952	1.750		1.869		0.000		1.869			0.000
Remarks													
 Support (\$ in Millions)													
				FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	C	Nothing entered for Activity and Location. Location could not be determined.	1.401	1.289		1.495		0.000		1.495	Continuing	Continuing	0
Subtotal			1.401	1.289		1.495		0.000		1.495			0.000
Remarks													

UNCLASSIFIED

R-1 Line Item #69

Page 8 of 41

376 of 1922

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army											DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 808: <i>DOD DRUG & VACC AD</i>					
Test and Evaluation (\$ in Millions)													
				FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	C	Nothing entered for Activity and Location. Location could not be determined.	33.699	2.574		2.331		0.000		2.331	Continuing	Continuing	0
Subtotal			33.699	2.574		2.331		0.000		2.331			0.000
Remarks													
Management Services (\$ in Millions)													
				FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	C	Nothing entered for Activity and Location. Location could not be determined.	7.197	1.216		1.530		0.000		1.530	Continuing	Continuing	0
Subtotal			7.197	1.216		1.530		0.000		1.530			0.000
Remarks													

UNCLASSIFIED

R-1 Line Item #69

Page 9 of 41

377 of 1922

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army							DATE: February 2010					
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>			PROJECT 808: <i>DOD DRUG & VACC AD</i>					
		Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals		48.249	6.829		7.225		0.000		7.225			0.000
Remarks												

UNCLASSIFIED

R-1 Line Item #69

Page 10 of 41

378 of 1922

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2011 Army																								DATE: February 2010			
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>												R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>												PROJECT 808: <i>DOD DRUG & VACC AD</i>			

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2011 Army			DATE: February 2010	
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)	R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev	PROJECT 808: DOD DRUG & VACC AD		
Schedule Details				
	Start		End	
Event	Quarter	Year	Quarter	Year
Leishmania Skin Test (CDR)	1	2009	1	2009
New Standard Military Topical Insect Repellant (MS-B)	1	2011	1	2011

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army								DATE: February 2010			
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 811: <i>MIL HIV VAC&DRUG DEV</i>			
COST (\$ in Millions)	FY 2009 Actual	FY 2010 Estimate	FY 2011 Base Estimate	FY 2011 OCO Estimate	FY 2011 Total Estimate	FY 2012 Estimate	FY 2013 Estimate	FY 2014 Estimate	FY 2015 Estimate	Cost To Complete	Total Cost
811: <i>MIL HIV VAC&DRUG DEV</i>	0.145	1.460	2.923	0.000	2.923	2.908	1.449	0.965	0.961	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification <p>This project funds development of militarily relevant human immunodeficiency virus (HIV) medical countermeasures. It provides for the planning and conduct of human clinical trials in a group of healthy volunteers to assess the drug/vaccine for safety, tolerability, how the drug/vaccine is distributed, metabolized, and excreted from the body, and to investigate the appropriate dose for therapeutic use. Development efforts are focused on militarily unique needs effecting manning, mobilization, and deployment. The major contractor is Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD. Research efforts are coordinated with the National Institutes of Health.</p>											
B. Accomplishments/Planned Program (\$ in Millions)											
							FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
Program #1 In FY09, evaluated potential commercial drug/vaccine candidates for preliminary human trials and conduct Design Readiness Review (DRR). <i>FY 2009 Accomplishments:</i> FY 2009 <i>FY 2010 Plans:</i> FY 2010 <i>FY 2011 Base Plans:</i> FY 2011 Base <i>FY 2011 OCO Plans:</i> FY 2011 OCO							0.145	0.000	0.000	0.000	0.000

UNCLASSIFIED

R-1 Line Item #69

Page 13 of 41

381 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army				DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)		R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev		PROJECT 811: MIL HIV VAC&DRUG DEV		
B. Accomplishments/Planned Program (\$ in Millions)						
		FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
Program #2 In FY10, will evaluate and down-select drug/vaccine candidates for preliminary human trials and conduct Design Readiness Review (DRR). FY 2009 Accomplishments: FY 2009 FY 2010 Plans: FY 2010 FY 2011 Base Plans: FY 2011 Base FY 2011 OCO Plans: FY 2011 OCO		0.000	1.419	0.000	0.000	0.000
Program #3 In FY11, will seek new industry partnership for selected candidate(s) drug/vaccine for HIV medical treatment/ prevention. FY 2009 Accomplishments: FY 2009 FY 2010 Plans: FY 2010 FY 2011 Base Plans: FY 2011 Base		0.000	0.000	2.923	0.000	2.923

UNCLASSIFIED

R-1 Line Item #69

Page 14 of 41

382 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army				DATE: February 2010	
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>		R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>		PROJECT 811: <i>MIL HIV VAC&DRUG DEV</i>	
<u>B. Accomplishments/Planned Program (\$ in Millions)</u>					
	FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
<i>FY 2011 OCO Plans:</i> FY 2011 OCO					
Program #4 Small Business Innovative Research/Small Business Technology Transfer Programs. <i>FY 2009 Accomplishments:</i> FY 2009 <i>FY 2010 Plans:</i> FY 2010 <i>FY 2011 Base Plans:</i> FY 2011 Base <i>FY 2011 OCO Plans:</i> FY 2011 OCO	0.000	0.041	0.000	0.000	0.000
Accomplishments/Planned Programs Subtotals	0.145	1.460	2.923	0.000	2.923
<u>C. Other Program Funding Summary (\$ in Millions)</u> N/A					
<u>D. Acquisition Strategy</u> Test and evaluate commercially developed drug/vaccine candidates in government-managed trials.					
<u>E. Performance Metrics</u> Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.					

UNCLASSIFIED

R-1 Line Item #69

Page 15 of 41

383 of 1922

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army											DATE: February 2010																																																			
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 811: <i>MIL HIV VAC&DRUG DEV</i>																																																						
<p>Product Development (\$ in Millions)</p> <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2">Cost Category Item</th> <th rowspan="2">Contract Method & Type</th> <th rowspan="2">Performing Activity & Location</th> <th rowspan="2">Total Prior Years Cost</th> <th colspan="2">FY 2010</th> <th colspan="2">FY 2011 Base</th> <th colspan="2">FY 2011 OCO</th> <th>FY 2011 Total</th> <th rowspan="2">Cost To Complete</th> <th rowspan="2">Total Cost</th> <th rowspan="2">Target Value of Contract</th> </tr> <tr> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> </tr> </thead> <tbody> <tr> <td>Product Development</td> <td align="center">C</td> <td>Henry M. Jackson Foundation Rockville, MD</td> <td align="right">5.139</td> <td align="right">0.347</td> <td></td> <td align="right">0.746</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.746</td> <td align="center">Continuing</td> <td align="center">Continuing</td> <td align="right">0</td> </tr> <tr> <td align="right" colspan="3">Subtotal</td><td align="right">5.139</td><td align="right">0.347</td><td></td><td align="right">0.746</td><td></td><td align="right">0.000</td><td></td><td align="right">0.746</td><td></td><td></td><td align="right">0.000</td> </tr> </tbody> </table> <p><u>Remarks</u></p>														Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Product Development	C	Henry M. Jackson Foundation Rockville, MD	5.139	0.347		0.746		0.000		0.746	Continuing	Continuing	0	Subtotal			5.139	0.347		0.746		0.000		0.746			0.000
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract																																																	
				Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost																																																				
Product Development	C	Henry M. Jackson Foundation Rockville, MD	5.139	0.347		0.746		0.000		0.746	Continuing	Continuing	0																																																	
Subtotal			5.139	0.347		0.746		0.000		0.746			0.000																																																	
<p>Support (\$ in Millions)</p> <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2">Cost Category Item</th> <th rowspan="2">Contract Method & Type</th> <th rowspan="2">Performing Activity & Location</th> <th rowspan="2">Total Prior Years Cost</th> <th colspan="2">FY 2010</th> <th colspan="2">FY 2011 Base</th> <th colspan="2">FY 2011 OCO</th> <th>FY 2011 Total</th> <th rowspan="2">Cost To Complete</th> <th rowspan="2">Total Cost</th> <th rowspan="2">Target Value of Contract</th> </tr> <tr> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> </tr> </thead> <tbody> <tr> <td>No product/contract costs greater than \$1M individually</td> <td align="center">C</td> <td>Nothing entered for Activity and Location. Location could not be determined.</td> <td align="right">0.868</td> <td align="right">0.202</td> <td></td> <td align="right">0.597</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.597</td> <td align="center">Continuing</td> <td align="center">Continuing</td> <td align="right">0</td> </tr> <tr> <td align="right" colspan="3">Subtotal</td><td align="right">0.868</td><td align="right">0.202</td><td></td><td align="right">0.597</td><td></td><td align="right">0.000</td><td></td><td align="right">0.597</td><td></td><td></td><td align="right">0.000</td> </tr> </tbody> </table> <p><u>Remarks</u> Not Applicable</p>														Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	No product/contract costs greater than \$1M individually	C	Nothing entered for Activity and Location. Location could not be determined.	0.868	0.202		0.597		0.000		0.597	Continuing	Continuing	0	Subtotal			0.868	0.202		0.597		0.000		0.597			0.000
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract																																																	
				Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost																																																				
No product/contract costs greater than \$1M individually	C	Nothing entered for Activity and Location. Location could not be determined.	0.868	0.202		0.597		0.000		0.597	Continuing	Continuing	0																																																	
Subtotal			0.868	0.202		0.597		0.000		0.597			0.000																																																	

UNCLASSIFIED

R-1 Line Item #69

Page 16 of 41

384 of 1922

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army											DATE: February 2010																																																										
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 811: <i>MIL HIV VAC&DRUG DEV</i>																																																													
Test and Evaluation (\$ in Millions) <table border="1" style="width:100%; border-collapse: collapse; margin-top: 10px;"> <tr> <th colspan="4"></th> <th colspan="2">FY 2010</th> <th colspan="2">FY 2011 Base</th> <th colspan="2">FY 2011 OCO</th> <th>FY 2011 Total</th> <th colspan="3"></th> </tr> <tr> <th>Cost Category Item</th> <th>Contract Method & Type</th> <th>Performing Activity & Location</th> <th>Total Prior Years Cost</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Cost To Complete</th> <th>Total Cost</th> <th>Target Value of Contract</th> </tr> <tr> <td>Test and Evaluation</td> <td align="center">C</td> <td>U.S. Component AFRIMS Bangkok, APO, AP 96546-5000</td> <td align="right">11.495</td> <td align="right">0.705</td> <td></td> <td align="right">1.107</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">1.107</td> <td align="center">Continuing</td> <td align="center">Continuing</td> <td align="right">0</td> </tr> <tr> <td align="right" colspan="3">Subtotal</td> <td align="right">11.495</td> <td align="right">0.705</td> <td></td> <td align="right">1.107</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">1.107</td> <td></td> <td></td> <td align="right">0.000</td> </tr> </table>																		FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total				Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	Test and Evaluation	C	U.S. Component AFRIMS Bangkok, APO, AP 96546-5000	11.495	0.705		1.107		0.000		1.107	Continuing	Continuing	0	Subtotal			11.495	0.705		1.107		0.000		1.107			0.000
				FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total																																																											
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract																																																								
Test and Evaluation	C	U.S. Component AFRIMS Bangkok, APO, AP 96546-5000	11.495	0.705		1.107		0.000		1.107	Continuing	Continuing	0																																																								
Subtotal			11.495	0.705		1.107		0.000		1.107			0.000																																																								
Remarks Not Applicable																																																																					
Management Services (\$ in Millions) <table border="1" style="width:100%; border-collapse: collapse; margin-top: 10px;"> <tr> <th colspan="4"></th> <th colspan="2">FY 2010</th> <th colspan="2">FY 2011 Base</th> <th colspan="2">FY 2011 OCO</th> <th>FY 2011 Total</th> <th colspan="3"></th> </tr> <tr> <th>Cost Category Item</th> <th>Contract Method & Type</th> <th>Performing Activity & Location</th> <th>Total Prior Years Cost</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Cost To Complete</th> <th>Total Cost</th> <th>Target Value of Contract</th> </tr> <tr> <td>No product/contract costs greater than \$1M individually.</td> <td align="center">C</td> <td>Nothing entered for Activity and Location. Location could not be determined.</td> <td align="right">0.250</td> <td align="right">0.206</td> <td></td> <td align="right">0.473</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.473</td> <td align="center">Continuing</td> <td align="center">Continuing</td> <td align="right">0</td> </tr> <tr> <td align="right" colspan="3">Subtotal</td> <td align="right">0.250</td> <td align="right">0.206</td> <td></td> <td align="right">0.473</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.473</td> <td></td> <td></td> <td align="right">0.000</td> </tr> </table>																		FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total				Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	No product/contract costs greater than \$1M individually.	C	Nothing entered for Activity and Location. Location could not be determined.	0.250	0.206		0.473		0.000		0.473	Continuing	Continuing	0	Subtotal			0.250	0.206		0.473		0.000		0.473			0.000
				FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total																																																											
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract																																																								
No product/contract costs greater than \$1M individually.	C	Nothing entered for Activity and Location. Location could not be determined.	0.250	0.206		0.473		0.000		0.473	Continuing	Continuing	0																																																								
Subtotal			0.250	0.206		0.473		0.000		0.473			0.000																																																								
Remarks Not Applicable																																																																					

UNCLASSIFIED

R-1 Line Item #69

Page 17 of 41

385 of 1922

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army							DATE: February 2010											
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>			PROJECT 811: <i>MIL HIV VAC&DRUG DEV</i>											
<div style="display: flex; justify-content: space-between;"> <div style="width: 25%;"></div> <div style="width: 20%; text-align: center;"> Total Prior Years Cost </div> <div style="width: 10%; text-align: center;"> FY 2010 </div> <div style="width: 10%; text-align: center;"> FY 2011 Base </div> <div style="width: 10%; text-align: center;"> FY 2011 OCO </div> <div style="width: 10%; text-align: center;"> FY 2011 Total </div> <div style="width: 10%; text-align: center;"> Cost To Complete </div> <div style="width: 10%; text-align: center;"> Total Cost </div> <div style="width: 10%; text-align: center;"> Target Value of Contract </div> </div> <table border="1" style="width:100%; border-collapse: collapse; margin-top: 5px;"> <tr> <td style="width: 25%; text-align: right;">Project Cost Totals</td> <td style="width: 20%; text-align: center;">17.752</td> <td style="width: 10%; text-align: center;">1.460</td> <td style="width: 10%; text-align: center;">2.923</td> <td style="width: 10%; text-align: center;">0.000</td> <td style="width: 10%; text-align: center;">2.923</td> <td style="width: 10%;"></td> <td style="width: 10%;"></td> <td style="width: 10%; text-align: center;">0.000</td> </tr> </table>										Project Cost Totals	17.752	1.460	2.923	0.000	2.923			0.000
Project Cost Totals	17.752	1.460	2.923	0.000	2.923			0.000										
Remarks																		

UNCLASSIFIED

UNCLASSIFIED

Army

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2011 Army			DATE: February 2010	
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 811: <i>MIL HIV VAC&DRUG DEV</i>		
Schedule Details				
	Start		End	
Event	Quarter	Year	Quarter	Year
HIV Vaccine Design Readiness Review (DRR)	3	2010	3	2010

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army								DATE: February 2010			
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 836: <i>Field Medical Systems Advanced Development</i>			
COST (\$ in Millions)	FY 2009 Actual	FY 2010 Estimate	FY 2011 Base Estimate	FY 2011 OCO Estimate	FY 2011 Total Estimate	FY 2012 Estimate	FY 2013 Estimate	FY 2014 Estimate	FY 2015 Estimate	Cost To Complete	Total Cost
836: <i>Field Medical Systems Advanced Development</i>	13.343	22.822	17.984	0.000	17.984	21.888	11.833	7.492	7.645	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification <p>This project funds development of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project funds human clinical trials to test the safety and effectiveness of biologics (products derived from living organisms) and devices necessary to meet medical requirements. When available, commercially-off-the-shelf (COTS) medical products are also tested and evaluated for transition to system development and demonstration. Consideration is also given to reducing the medical logistics footprint through smaller weight, volume, and equipment independence from supporting materials. All clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations. In FY10 Project 837 Soldier Sys Prot-AD will be consolidated into this Project, 836. Major contractors/intra-governmental agencies include: IGR Enterprises, Inc.; Army Medical Department Board Test Center; SeQual Technologies, Inc.; Ultrasonic Diagnostics, Inc.; HemCon Medical Technologies, Inc.; Hemerus Medical, LLC.; Fast Track Drugs & Biologics, LLC; Clinical Research Management, and Walter Reed Army Institute of Research (WRAIR) and Institute of Surgical Research (ISR) for user evaluation.</p>											
B. Accomplishments/Planned Program (\$ in Millions)											
						FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total	
Program #1 In FY09, the Ceramic Oxygen Generator (COG) transitioned to project 832 for Systems Development and Demonstration. Future Medical Shelter System (FMSS): down-selected to one system. Future Combat System (FCS): prepared for performance design review (PDR), and provided support to PM-Future Combat Systems Brigade Combat Team regarding Medical Mission package, treatment table, shelter, and patient movement items for form, fit, and function. Ultrasonic Brain Imager (UBI): conducted clinical user assessments, based on a down-select. Freeze-dried Plasma Program (hemorrhage treatment candidate): transitioned to project 832 for Systems Development and Demonstration. Intranasal Ketamine (low dose pain management via nasal spray): conducted a Pain Management Meeting with Combat Developer (representing Military requirements) and medical caregivers across roles of care to determine which pain management options are best for deployed hospitals, during medical						13.343	0.000	0.000	0.000	0.000	

UNCLASSIFIED

R-1 Line Item #69

Page 21 of 41

389 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army			DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)		R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev		PROJECT 836: Field Medical Systems Advanced Development	
B. Accomplishments/Planned Program (\$ in Millions)					
	FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
evacuation, and at far forward treatment facilities in austere environments. Red Blood Cell Extended Life (RBCXL) program (hemorrhage treatment candidate - a new blood collection and storage system that extends the shelf-life of red blood cells from 6 to 8 weeks): transitioned to project 832. Platelet Derived Hemostatic Agent (PDHA) (use of cryopreserved platelets for control of severe bleeding): conducted a feasibility clinical evaluation and conducted good manufacturing practices validation studies of the product. FY 2009 Accomplishments: FY 2009 FY 2010 Plans: FY 2010 FY 2011 Base Plans: FY 2011 Base FY 2011 OCO Plans: FY 2011 OCO					
Program #2 In FY10, will conduct human trial to assess intranasal ketamine drug effects on a subject's judgment. Antiplateque Gum: will transition from project 840 and will conduct small human safety and dose escalation study in health adults. Environmental Sentinel Biomonitor (ESB): transition increment 1 from project 837 and increment 2 from technology development project FH4, initiate development of increment 2 ESB system for use in conjunction with field water facilities. Field test one Ceramic Oxygen Generator system for the Force Provider Early Entry Combat Support Hospital (CSH). Transition Ultrasonic brain Imager product to project 832 for Systems Development and Demonstration.	0.000	22.240	0.000	0.000	0.000

UNCLASSIFIED

R-1 Line Item #69

Page 22 of 41

390 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army				DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)		R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev		PROJECT 836: Field Medical Systems Advanced Development		
B. Accomplishments/Planned Program (\$ in Millions)						
		FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
FY 2009 Accomplishments: FY 2009						
FY 2010 Plans: FY 2010						
FY 2011 Base Plans: FY 2011 Base						
FY 2011 OCO Plans: FY 2011 OCO						
Program #3 In FY 11, Total Intravenous Anesthesia (TIVA): will continue to perform clinical trials and submit required documents for FDA clearance/approval. Auto Critical Care System (ACCLS): will conduct validation testing and Army DT/OT/AWC will also be conducted. The 510K will be submitted for FDA review for modified devices. Urinary Facilitation Device: will continue testing, reports, and review for FDA approval.PEAK Surgical System (Plasma Blade): if preclinical results are favorable will conduct environmental testing and identify any needed design modifications to produce a fieldable unit. Will also pursue additional regulatory approvals as needed. Plasma Knife: if preclinical results are favorable, will conduct environmental testing and identify any needed design modifications to produce a fieldable unit. Will also pursue additional regulatory approvals as needed.Hydrosurgery System: will conduct operational and environmental testing. Remote Diagnostic Access (RDA): will develop software, conduct testing, and refinement for MOC Sensor Modulal Development phase. Treatment Table for PM, HBCT Medical Mission Package for Treatment Variants: will transition to Project 832. Refrigerator for PM, HBCT for Medical Mission Package for Treatment Variant: will transition to Project 832. Shock and Vibration Isolation System for Patient Litters in Ground and Air Medical Evacuation Vehicles: will transition to Project 832. Shelter for PM, HBCT for Medical Mission Package for Treatment Variant: will transition to Project 832. Passive Cold Chain Capability for Temperature Sensitive Medical Materiel: will		0.000	0.000	17.984	0.000	17.984

UNCLASSIFIED

R-1 Line Item #69

Page 23 of 41

391 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army			DATE: February 2010			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)	R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev	PROJECT 836: Field Medical Systems Advanced Development				
B. Accomplishments/Planned Program (\$ in Millions)						
		FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
transition to Project 832. The intranasal ketamine drug effects study will transition to project 832 for Systems Development and Demonstration . FY 2009 Accomplishments: FY 2009 FY 2010 Plans: FY 2010 FY 2011 Base Plans: FY 2011 Base FY 2011 OCO Plans: FY 2011 OCO						
Program #4 Small Business Innovative Research/Small Business Technology Transfer Programs FY 2009 Accomplishments: FY 2009 FY 2010 Plans: FY 2010 FY 2011 Base Plans: FY 2011 Base FY 2011 OCO Plans: FY 2011 OCO		0.000	0.582	0.000	0.000	0.000

UNCLASSIFIED

R-1 Line Item #69

Page 24 of 41

392 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army				DATE: February 2010				
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 836: <i>Field Medical Systems Advanced Development</i>						
<u>B. Accomplishments/Planned Program (\$ in Millions)</u>								
				FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
Accomplishments/Planned Programs Subtotals				13.343	22.822	17.984	0.000	17.984
<u>C. Other Program Funding Summary (\$ in Millions)</u> N/A								
<u>D. Acquisition Strategy</u> Develop in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding.								
<u>E. Performance Metrics</u> Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.								

UNCLASSIFIED

R-1 Line Item #69

Page 25 of 41

393 of 1922

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army											DATE: February 2010																																																																																																											
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 836: <i>Field Medical Systems Advanced Development</i>																																																																																																														
Product Development (\$ in Millions) <table border="1" style="width:100%; border-collapse: collapse; margin-top: 10px;"> <thead> <tr> <th rowspan="2">Cost Category Item</th> <th rowspan="2">Contract Method & Type</th> <th rowspan="2">Performing Activity & Location</th> <th rowspan="2">Total Prior Years Cost</th> <th colspan="2">FY 2010</th> <th colspan="2">FY 2011 Base</th> <th colspan="2">FY 2011 OCO</th> <th>FY 2011 Total</th> <th rowspan="2">Cost To Complete</th> <th rowspan="2">Total Cost</th> <th rowspan="2">Target Value of Contract</th> </tr> <tr> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> </tr> </thead> <tbody> <tr> <td>Clinical Research Management</td> <td align="center">C</td> <td>Hinckley OH</td> <td align="right">0.000</td> <td align="right">0.000</td> <td></td> <td align="right">1.133</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">1.133</td> <td align="center">Continuing</td> <td align="center">Continuing</td> <td align="right">0</td> </tr> <tr> <td>Allied Technologies & Consulting LLC</td> <td align="center">C</td> <td>Frederick MD</td> <td align="right">0.000</td> <td align="right">1.580</td> <td></td> <td align="right">2.000</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">2.000</td> <td align="center">Continuing</td> <td align="center">Continuing</td> <td align="right">0</td> </tr> <tr> <td>Aquila Alaska Corporation</td> <td align="center">C</td> <td>Wasilla AK</td> <td align="right">0.000</td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td align="center">Continuing</td> <td align="center">Continuing</td> <td align="right">0</td> </tr> <tr> <td>SeQual Technologies</td> <td align="center">C</td> <td>San Diego CA</td> <td align="right">0.000</td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td align="center">Continuing</td> <td align="center">Continuing</td> <td align="right">0</td> </tr> <tr> <td>No other contract exceeds \$1M</td> <td align="center">C</td> <td>Nothing entered for Activity and Location. Location could not be determined.</td> <td align="right">15.169</td> <td align="right">5.449</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td align="center">Continuing</td> <td align="center">Continuing</td> <td align="right">0</td> </tr> <tr> <td align="right" colspan="3">Subtotal</td><td align="right">15.169</td><td align="right">7.029</td><td></td><td align="right">3.133</td><td></td><td align="right">0.000</td><td></td><td align="right">3.133</td><td></td><td></td><td align="right">0.000</td> </tr> </tbody> </table>														Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Clinical Research Management	C	Hinckley OH	0.000	0.000		1.133		0.000		1.133	Continuing	Continuing	0	Allied Technologies & Consulting LLC	C	Frederick MD	0.000	1.580		2.000		0.000		2.000	Continuing	Continuing	0	Aquila Alaska Corporation	C	Wasilla AK	0.000	0.000		0.000		0.000		0.000	Continuing	Continuing	0	SeQual Technologies	C	San Diego CA	0.000	0.000		0.000		0.000		0.000	Continuing	Continuing	0	No other contract exceeds \$1M	C	Nothing entered for Activity and Location. Location could not be determined.	15.169	5.449		0.000		0.000		0.000	Continuing	Continuing	0	Subtotal			15.169	7.029		3.133		0.000		3.133			0.000
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract																																																																																																									
				Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost																																																																																																												
Clinical Research Management	C	Hinckley OH	0.000	0.000		1.133		0.000		1.133	Continuing	Continuing	0																																																																																																									
Allied Technologies & Consulting LLC	C	Frederick MD	0.000	1.580		2.000		0.000		2.000	Continuing	Continuing	0																																																																																																									
Aquila Alaska Corporation	C	Wasilla AK	0.000	0.000		0.000		0.000		0.000	Continuing	Continuing	0																																																																																																									
SeQual Technologies	C	San Diego CA	0.000	0.000		0.000		0.000		0.000	Continuing	Continuing	0																																																																																																									
No other contract exceeds \$1M	C	Nothing entered for Activity and Location. Location could not be determined.	15.169	5.449		0.000		0.000		0.000	Continuing	Continuing	0																																																																																																									
Subtotal			15.169	7.029		3.133		0.000		3.133			0.000																																																																																																									
Remarks																																																																																																																						

UNCLASSIFIED

R-1 Line Item #69

Page 26 of 41

394 of 1922

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army											DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 836: <i>Field Medical Systems Advanced Development</i>					
Support (\$ in Millions)													
				FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	C	Nothing entered for Activity and Location. Location could not be determined.	0.000	4.335		5.203		0.000		5.203	Continuing	Continuing	0
Subtotal			0.000	4.335		5.203		0.000		5.203			0.000
Remarks No product/contract costs greater than \$1M individually.													
Test and Evaluation (\$ in Millions)													
				FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$M individually.	C	Nothing entered for Activity and Location. Location could not be determined.	0.000	8.033		8.654		0.000		8.654	Continuing	Continuing	0
Subtotal			0.000	8.033		8.654		0.000		8.654			0.000
Remarks No product/contract costs greater than \$1M individually.													

UNCLASSIFIED

R-1 Line Item #69

Page 27 of 41

395 of 1922

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army											DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 836: <i>Field Medical Systems Advanced Development</i>					
Management Services (\$ in Millions)													
				FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$M individually.	C	Nothing entered for Activity and Location. Location could not be determined.	28.754	3.425		0.994		0.000		0.994	Continuing	Continuing	0
Subtotal			28.754	3.425		0.994		0.000		0.994			0.000
Remarks													
			Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals			43.923	22.822		17.984		0.000		17.984			0.000
Remarks													

UNCLASSIFIED

R-1 Line Item #69

Page 28 of 41

396 of 1922

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2011 Army			DATE: February 2010
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 836: <i>Field Medical Systems Advanced Development</i>	

[illegible]

UNCLASSIFIED

R-1 Line Item #69

Page 29 of 41

397 of 1922

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2011 Army			DATE: February 2010	
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>		R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>		PROJECT 836: <i>Field Medical Systems Advanced Development</i>

Schedule Details

Event	Start		End	
	Quarter	Year	Quarter	Year
Future Combat Systems (CDR)	3	2009	3	2009

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army								DATE: February 2010			
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 837: <i>SOLDIER SYS PROT-AD</i>			
COST (\$ in Millions)	FY 2009 Actual	FY 2010 Estimate	FY 2011 Base Estimate	FY 2011 OCO Estimate	FY 2011 Total Estimate	FY 2012 Estimate	FY 2013 Estimate	FY 2014 Estimate	FY 2015 Estimate	Cost To Complete	Total Cost
837: <i>SOLDIER SYS PROT-AD</i>	6.561	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification <p>This project funds development of preventive medicine materiel, including devices and medicines, in order to provide protection, sustainment, and enhancement of the physical and psychological capabilities of Soldiers across the Army's full spectrum operations. Focus is on the reduction of personnel losses due to preventable disease and non-battle injuries through development of environmental and physiological performance monitors and other preventive medicine countermeasures. In FY10, Project 837 will be consolidated into Project 836 Combat Medical Matl AD. Major contractors are Pacific Technologies, Inc, Redwood, WA, and Agave Biosystems Inc, Austin, TX.</p>											
B. Accomplishments/Planned Program (\$ in Millions)											
							FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
Program #1 Coliform Analyzer: In FY09, conduct technical testing and user evaluation and transition to project 834 for System Development and Demonstration. Environmental Sentinel Biomonitor (ESB): In 2Q FY09, conduct Milestone B (for increment 1 ESB system). In FY10, project 837 is consolidated into project 836. <i>FY 2009 Accomplishments:</i> FY 2009 <i>FY 2010 Plans:</i> FY 2010 <i>FY 2011 Base Plans:</i> FY 2011 Base							6.561	0.000	0.000	0.000	0.000

UNCLASSIFIED

R-1 Line Item #69

Page 31 of 41

399 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army				DATE: February 2010	
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>		R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>		PROJECT 837: <i>SOLDIER SYS PROT-AD</i>	
<u>B. Accomplishments/Planned Program (\$ in Millions)</u>					
		FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO
<i>FY 2011 OCO Plans:</i> FY 2011 OCO					
Accomplishments/Planned Programs Subtotals		6.561	0.000	0.000	0.000
<u>C. Other Program Funding Summary (\$ in Millions)</u> N/A					
<u>D. Acquisition Strategy</u> Test and evaluate materiel in-house and commercially developed preventative medicine materiel to meet FDA and EPA regulatory requirements.					
<u>E. Performance Metrics</u> Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.					

UNCLASSIFIED

R-1 Line Item #69

Page 32 of 41

400 of 1922

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army											DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 837: <i>SOLDIER SYS PROT-AD</i>					
Product Development (\$ in Millions)													
				FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	C	Nothing entered for Activity and Location. Location could not be determined.	3.661	0.000		0.000		0.000		0.000	Continuing	Continuing	0
Subtotal			3.661	0.000		0.000		0.000		0.000			0.000
Remarks													
Support (\$ in Millions)													
				FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	C	Nothing entered for Activity and Location. Location could not be determined.	0.247	0.000		0.000		0.000		0.000	Continuing	Continuing	0
Subtotal			0.247	0.000		0.000		0.000		0.000			0.000
Remarks													

UNCLASSIFIED

R-1 Line Item #69

Page 33 of 41

401 of 1922

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army											DATE: February 2010																																																			
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT 837: <i>SOLDIER SYS PROT-AD</i>																																																						
<p>Test and Evaluation (\$ in Millions)</p> <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2">Cost Category Item</th> <th rowspan="2">Contract Method & Type</th> <th rowspan="2">Performing Activity & Location</th> <th rowspan="2">Total Prior Years Cost</th> <th colspan="2">FY 2010</th> <th colspan="2">FY 2011 Base</th> <th colspan="2">FY 2011 OCO</th> <th>FY 2011 Total</th> <th rowspan="2">Cost To Complete</th> <th rowspan="2">Total Cost</th> <th rowspan="2">Target Value of Contract</th> </tr> <tr> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> </tr> </thead> <tbody> <tr> <td>No product/contract costs greater than \$1M individually</td> <td align="center">C</td> <td>Research and development; stability and potency testing Location could not be determined.</td> <td align="right">1.276</td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td align="center">Continuing</td> <td align="center">Continuing</td> <td align="right">0</td> </tr> <tr> <td align="right" colspan="3">Subtotal</td><td align="right">1.276</td><td align="right">0.000</td><td></td><td align="right">0.000</td><td></td><td align="right">0.000</td><td></td><td align="right">0.000</td><td></td><td></td><td align="right">0.000</td> </tr> </tbody> </table> <p><u>Remarks</u></p>														Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	No product/contract costs greater than \$1M individually	C	Research and development; stability and potency testing Location could not be determined.	1.276	0.000		0.000		0.000		0.000	Continuing	Continuing	0	Subtotal			1.276	0.000		0.000		0.000		0.000			0.000
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract																																																	
				Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost																																																				
No product/contract costs greater than \$1M individually	C	Research and development; stability and potency testing Location could not be determined.	1.276	0.000		0.000		0.000		0.000	Continuing	Continuing	0																																																	
Subtotal			1.276	0.000		0.000		0.000		0.000			0.000																																																	
<p>Management Services (\$ in Millions)</p> <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2">Cost Category Item</th> <th rowspan="2">Contract Method & Type</th> <th rowspan="2">Performing Activity & Location</th> <th rowspan="2">Total Prior Years Cost</th> <th colspan="2">FY 2010</th> <th colspan="2">FY 2011 Base</th> <th colspan="2">FY 2011 OCO</th> <th>FY 2011 Total</th> <th rowspan="2">Cost To Complete</th> <th rowspan="2">Total Cost</th> <th rowspan="2">Target Value of Contract</th> </tr> <tr> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> <th>Award Date</th> <th>Cost</th> </tr> </thead> <tbody> <tr> <td>No product/contract costs greater than \$1M individually</td> <td align="center">C</td> <td>Nothing entered for Activity and Location. Location could not be determined.</td> <td align="right">2.472</td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td></td> <td align="right">0.000</td> <td align="center">Continuing</td> <td align="center">Continuing</td> <td align="right">0</td> </tr> <tr> <td align="right" colspan="3">Subtotal</td><td align="right">2.472</td><td align="right">0.000</td><td></td><td align="right">0.000</td><td></td><td align="right">0.000</td><td></td><td align="right">0.000</td><td></td><td></td><td align="right">0.000</td> </tr> </tbody> </table> <p><u>Remarks</u></p>														Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	No product/contract costs greater than \$1M individually	C	Nothing entered for Activity and Location. Location could not be determined.	2.472	0.000		0.000		0.000		0.000	Continuing	Continuing	0	Subtotal			2.472	0.000		0.000		0.000		0.000			0.000
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	FY 2010		FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract																																																	
				Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost																																																				
No product/contract costs greater than \$1M individually	C	Nothing entered for Activity and Location. Location could not be determined.	2.472	0.000		0.000		0.000		0.000	Continuing	Continuing	0																																																	
Subtotal			2.472	0.000		0.000		0.000		0.000			0.000																																																	

UNCLASSIFIED

R-1 Line Item #69

Page 34 of 41

402 of 1922

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2011 Army							DATE: February 2010				
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev			PROJECT 837: SOLDIER SYS PROT-AD				
		Total Prior Years Cost	FY 2010	FY 2011 Base		FY 2011 OCO		FY 2011 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals		7.656	0.000	0.000		0.000		0.000			0.000
Remarks											

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2011 Army		DATE: February 2010
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 837: <i>SOLDIER SYS PROT-AD</i>

[illegible]

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2011 Army			DATE: February 2010	
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>	R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>	PROJECT 837: <i>SOLDIER SYS PROT-AD</i>		
Schedule Details				
	Start		End	
Event	Quarter	Year	Quarter	Year
Environmental Sentinel Biomonitor (2nd QTR FY 09)	1	2009	1	2009

UNCLASSIFIED

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army								DATE: February 2010			
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>				R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>				PROJECT CS4: <i>MEDICAL SYSTEMS ADV DEV INITIATIVES (CA)</i>			
COST (\$ in Millions)	FY 2009 Actual	FY 2010 Estimate	FY 2011 Base Estimate	FY 2011 OCO Estimate	FY 2011 Total Estimate	FY 2012 Estimate	FY 2013 Estimate	FY 2014 Estimate	FY 2015 Estimate	Cost To Complete	Total Cost
CS4: <i>MEDICAL SYSTEMS ADV DEV INITIATIVES (CA)</i>	3.988	4.775	0.000	0.000	0.000	0.000	0.000	0.000	0.000	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification Congressional Interest Item funding for medical systems advanced development initiatives											
B. Accomplishments/Planned Program (\$ in Millions)											
							FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
Program #1 Small Business Innovative Research/Small Business Technology Transfer Program <i>FY 2009 Accomplishments:</i> FY 2009 <i>FY 2010 Plans:</i> FY 2010 <i>FY 2011 Base Plans:</i> FY 2011 Base <i>FY 2011 OCO Plans:</i> FY 2011 OCO							0.113	0.000	0.000	0.000	0.000
Program #2 Congressionally directed project to conduct advanced development research in Leishmaniasis Skin Test Antigen.							0.775	0.000	0.000	0.000	0.000

UNCLASSIFIED

R-1 Line Item #69

Page 38 of 41

406 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army			DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)	R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev	PROJECT CS4: MEDICAL SYSTEMS ADV DEV INITIATIVES (CA)			
B. Accomplishments/Planned Program (\$ in Millions)					
	FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
FY 2009 Accomplishments: FY 2009					
FY 2010 Plans: FY 2010					
FY 2011 Base Plans: FY 2011 Base					
FY 2011 OCO Plans: FY 2011 OCO					
Program #3 Congressionally directed project to conduct advanced development research in Garment Based Physiological Monitoring system FY 2009 Accomplishments: FY 2009 FY 2010 Plans: FY 2010 FY 2011 Base Plans: FY 2011 Base FY 2011 OCO Plans: FY 2011 OCO	1.550	0.000	0.000	0.000	0.000
Program #4	1.550	2.400	0.000	0.000	0.000

UNCLASSIFIED

R-1 Line Item #69

Page 39 of 41

407 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army				DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)		R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev		PROJECT CS4: MEDICAL SYSTEMS ADV DEV INITIATIVES (CA)		
B. Accomplishments/Planned Program (\$ in Millions)						
		FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
Congressionally directed project to conduct advanced development research in Wireless Med monitoring system FY 2009 Accomplishments: FY 2009 FY 2010 Plans: FY 2010 FY 2011 Base Plans: FY 2011 Base FY 2011 OCO Plans: FY 2011 OCO						
Program #5 Congressionally directed project to conduct execution of a Quality Systems Program for FDA Regulation Activities FY 2009 Accomplishments: FY 2009 FY 2010 Plans: FY 2010 FY 2011 Base Plans: FY 2011 Base FY 2011 OCO Plans: FY 2011 OCO		0.000	1.175	0.000	0.000	0.000

UNCLASSIFIED

R-1 Line Item #69

Page 40 of 41

408 of 1922

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2011 Army				DATE: February 2010		
APPROPRIATION/BUDGET ACTIVITY 2040: <i>Research, Development, Test & Evaluation, Army</i> BA 4: <i>Advanced Component Development & Prototypes (ACD&P)</i>		R-1 ITEM NOMENCLATURE PE 0603807A: <i>Medical Systems - Adv Dev</i>		PROJECT CS4: <i>MEDICAL SYSTEMS ADV DEV INITIATIVES (CA)</i>		
<u>B. Accomplishments/Planned Program (\$ in Millions)</u>						
		FY 2009	FY 2010	FY 2011 Base	FY 2011 OCO	FY 2011 Total
Program #6 Congressionally directed project to study Model for Green Laboratories and Clean Rooms <i>FY 2009 Accomplishments:</i> FY 2009 <i>FY 2010 Plans:</i> FY 2010 <i>FY 2011 Base Plans:</i> FY 2011 Base <i>FY 2011 OCO Plans:</i> FY 2011 OCO		0.000	1.200	0.000	0.000	0.000
Accomplishments/Planned Programs Subtotals		3.988	4.775	0.000	0.000	0.000
<u>C. Other Program Funding Summary (\$ in Millions)</u> N/A						
<u>D. Acquisition Strategy</u> N/A						
<u>E. Performance Metrics</u> Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.						

UNCLASSIFIED

R-1 Line Item #69

Page 41 of 41

409 of 1922